Invokana Lawsuit TV Commercial

Published on June 24, 2015 by admin

Text-Size:A A A+

If you recently experienced symptoms of ketoacidosis, acidosis, ketosis or diabetic ketoacidosis (DKA) as described in Invokana lawsuit commercials airing throughout the country, now is the time to contact our Firm. The attorneys at Bernstein Liebhard LLP are eager to provide legal help to anyone who was hospitalized for these conditions while using Invokana or a similar Type 2 diabetes drug.

If you suffered health issues described in numerous Invokana lawsuit commercials that have aired recently, it is imperative that you pursue legal counsel right away. The above conditions can lead to diabetic coma, kidney failure and even death. Call us now at 212-779-1414.

What is Invokana?

Invokana is a type of Type 2 diabetes medication that belongs to a class referred to as sodium-glucose cotransporter-2 (SGLT2) inhibitors. These medications were designed to lower blood sugar by eliminating glucose through urination. Approved by the U.S. Food and Drug Administration (FDA) in March 2013, Invokana is prescribed in 100 and 300 mg tablets.

The possibility that Invokana and other Type 2 diabetes drugs in its class could be associated with the onset of diabetic ketoacidosis have led numerous law firms to urge patients who may have suffered this complication to file a lawsuit against their manufacturers. In May 2015, the U.S. Food and Drug Administration (FDA) announced a safety review of SGLT2 inhibitors after finding 20 reports of acidosis–logged in its database as diabetic ketoacidosis (DKA), ketoacidosis and ketosis– occurring among people taking the drugs from May 2013 until June 6, 2014. Patients in all these cases required emergency room treatment or hospitalization, the federal agency wrote.

As described in Invokana commercial advertisements, the below are symptoms of acidosis, ketoacidosis and diabetic ketoacidosis (DKA):

  • Breathing difficulty
  • Changes in urination
  • Confusion
  • Nausea and vomiting
  • Anorexia
  • Weakness
  • Lethargy (unusual fatigue or sleepiness)

At the time of its announcement, the FDA was reviewing the safety of all SGLT2 inhibitors to assess whether the risk for ketoacidosis should be included on their warning labels. In addition to Invokana, the following medications belong to the class:

  • Invokamet (canagliflozin and metformin)
  • Farxiga (dapagliflozin) (Approved by FDA on January 8, 2014)
  • Xigduo XR (dapagliflozin and metformin extended-release)
  • Jardiance (empagliflozin) (Approved by FDA on August 1, 2014)
  • Glyxambi (empagliflozin and linagliptin)

If you or a loved one experience any symptoms of diabetic ketoacidosis after taking Invokana or another SGLT2 inhibitor, it’s vital that you act fast. If not treated quickly, ketoacidosis can lead to a diabetic coma or even death.

As noted in some Invokana lawsuit commercials, the cases of ketoacidosis that have been reported are peculiar, since the condition is typically seen in individuals with Type 1 diabetes. More often than not, symptoms were present about two weeks after patients began taking the drug.

Have You Seen an Invokana Lawsuit Commercial? Call Us.

If you were hospitalized with ketoacidosis that may be related to treatment with Invokana, the time is now to file a claim. Contact the attorneys at Bernstein Liebhard LLP for legal advice on how to seek compensation for out-of-pocket medical expenses, lost wages, and other damages you might have incurred as a result of your exposure to Invokana or another SGLT2 inhibitor. Call us today for a free and confidential case evaluation: 212-779-1414.

Web Analytics